Raphael Pharmaceutical Discloses $1,000 Cash Balance and Going Concern Warning

summarizeSummary

Raphael Pharmaceutical's Q2 2026 10-Q shows cash of just $1,000, a going concern warning, and a need for $2 million in near-term financing. Authorized shares were increased to 50 million, and the CFO resigned.

check_boxKey Events · Earnings and Guidance · RAPH

• Cash Balance Collapses to $1,000

  Cash and cash equivalents fell to $1,000 as of June 30, 2026, from $45,000 at December 31, 2025. Management states existing cash will not fund operations through Q3 2026.

• Going Concern Warning Reiterated

  The company reiterates substantial doubt about its ability to continue as a going concern and states it needs approximately $2 million over the next 12 months for R&D and operating costs.

• Authorized Shares Increased to 50 Million

  Authorized common shares increased from 21,020,560 to 50,000,000, creating significant headroom for future equity issuance and potential dilution.

• CFO and General Counsel Resigns

  Guy Ofir resigned as CFO, General Counsel, and Director effective July 16, 2026. Uri Tadelis was appointed CFO.

auto_awesomeAnalysis · RAPH · Life Sciences

The Q2 2026 10-Q from Raphael Pharmaceutical reveals a critically low cash position of $1,000, down from $45,000 at year-end 2025. Management explicitly states that existing cash will not fund operations through the third quarter of 2026 and that the company needs approximately $2 million over the next 12 months. Authorized shares were also increased from 21.0 million to 50.0 million, signaling potential future dilution. The going concern warning is reiterated, and the CFO/General Counsel resigned effective July 16, 2026. This represents a material deterioration in liquidity and a clear survival risk for the company.